Literature DB >> 4208567

Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis.

K Takayama, L Wang, H L David.   

Abstract

When an actively growing culture of the H37Ra strain of Mycobacterium tuberculosis was exposed to isoniazid at a concentration of 0.5 mug/ml, the cells began to lose their ability to synthesize mycolic acids immediately. After 60 min, the cells had completely lost this ability. The synthesis of the three mycolate components-alpha-mycolate, methoxymycolate, and beta-mycolate-was inhibited. The viability of the isoniazid-treated cells was unaffected up to about 60 min of exposure, after which time there was a gradual decline in the viability to about 18% after 180 min. Correspondingly, growth of the drug-treated cells slowed down and stopped after 24 hr. The inhibition of the synthesis of mycolic acids was reversible if the drug was removed before the loss of viability set in. Incubation of the viable cells in the absence of the drug for 24 hr restored the mycolate synthesis. These results strongly suggest that the inhibition of the synthesis of the mycolic acids is closely associated with the primary mechanism of action of isoniazid on the tubercle bacilli. The sequence of events which leads to the loss of viability of cells exposed to isoniazid is described.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4208567      PMCID: PMC444261          DOI: 10.1128/AAC.2.1.29

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Enzymatic synthesis of cyclopropane fatty acids catalyzed by bacterial extracts.

Authors:  H ZALKIN; J H LAW; H GOLDFINE
Journal:  J Biol Chem       Date:  1963-04       Impact factor: 5.157

2.  Selective inhibition of nucleic acid synthesis in Mycobacterium tuberculosis by isoniazid.

Authors:  P R GANGADHARAM; F M HAROLD; W B SCHAEFER
Journal:  Nature       Date:  1963-05-18       Impact factor: 49.962

3.  Effect of isoniazid on the dehydrogenase activity of Mycobacterium tuberculosis.

Authors:  W B SCHAEFER
Journal:  J Bacteriol       Date:  1960-02       Impact factor: 3.490

4.  The bactericidal action of isoniazid, streptomycin and terramycin on extracellular and intracellular tubercle bacilli.

Authors:  G B MACKANESS; N SMITH
Journal:  Am Rev Tuberc       Date:  1953-03

5.  Mode of action of isoniazid.

Authors:  W R BARCLAY; R H EBERT; D KOCHWESER
Journal:  Am Rev Tuberc       Date:  1953-04

6.  Enzymatic alkylenation of phospholipid fatty acid chains by extracts of Mycobacterium phlei.

Authors:  Y Akamatsu; J H Law
Journal:  J Biol Chem       Date:  1970-02-25       Impact factor: 5.157

7.  Studies on the mycolic acids from human tubercle bacilli.

Authors:  D E Minnikin; N Polgar
Journal:  Tetrahedron Lett       Date:  1966-06       Impact factor: 2.415

8.  Effect of isoniazid on biosynthesis in Mycobacterium tuberculosis var. bovis BCG.

Authors:  J W Wimpenny
Journal:  J Gen Microbiol       Date:  1967-06

9.  Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis.

Authors:  F G Winder; P B Collins
Journal:  J Gen Microbiol       Date:  1970-09

10.  The lipids of Mycobacterium tuberculosis BCG: fractionation, composition, turnover and the effects of isoniazid.

Authors:  P J Brennan; S A Rooney; F G Winder
Journal:  Ir J Med Sci       Date:  1970-08       Impact factor: 1.568

View more
  87 in total

1.  Isoniazid inhibition of the synthesis of monounsaturated long-chain fatty acids in Mycobacterium tuberculosis H37Ra.

Authors:  L A Davidson; K Takayama
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

2.  Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis.

Authors:  B Phetsuksiri; A R Baulard; A M Cooper; D E Minnikin; J D Douglas; G S Besra; P J Brennan
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis.

Authors:  V R Bollela; E I Namburete; C S Feliciano; D Macheque; L H Harrison; J A Caminero
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

4.  Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis.

Authors:  Argyrides Argyrou; Lianji Jin; Linda Siconilfi-Baez; Ruth H Angeletti; John S Blanchard
Journal:  Biochemistry       Date:  2006-11-28       Impact factor: 3.162

5.  AccD6, a member of the Fas II locus, is a functional carboxyltransferase subunit of the acyl-coenzyme A carboxylase in Mycobacterium tuberculosis.

Authors:  Jaiyanth Daniel; Tae-Jin Oh; Chang-Muk Lee; Pappachan E Kolattukudy
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

6.  Galactosyl transferases in mycobacterial cell wall synthesis.

Authors:  Martina Belánová; Petronela Dianisková; Patrick J Brennan; Gladys C Completo; Natisha L Rose; Todd L Lowary; Katarína Mikusová
Journal:  J Bacteriol       Date:  2007-11-30       Impact factor: 3.490

7.  Isonicotinic acid hydrazide induced changes and inhibition in mycolic acid synthesis in Nocardia and related taxa.

Authors:  I Tomiyasu; I Yano
Journal:  Arch Microbiol       Date:  1984-04       Impact factor: 2.552

8.  Inhibition by ethambutol of mycolic acid transfer into the cell wall of Mycobacterium smegmatis.

Authors:  K Takayama; E L Armstrong; K A Kunugi; J O Kilburn
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

9.  Targeted replacement of the mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks mycosides.

Authors:  A K Azad; T D Sirakova; L M Rogers; P E Kolattukudy
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

10.  Effect of isoniazid on the protoplasmic viscosity in Mycobacterium tuberculosis.

Authors:  K Takayama; A D Keith; W Snipes
Journal:  Antimicrob Agents Chemother       Date:  1975-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.